Chemistry:Minzasolmin
From HandWiki
Minzasolmin (development names DLX313 and UCB0599) is an experimental small-molecule drug in development for Parkinson's disease that is designed to prevent misfolding of α-synuclein.[1][2] On December 16, 2024 UCB reported the results of a phase II clinical trial on minzasolmin for Parkinson's involving 496 people, stating that the drug failed to demonstrate superiority over placebo in both primary and secondary endpoints.[3]
See also
- Anti-α-synuclein drug
- List of investigational Parkinson's disease drugs
References
- ↑ Schwarz, Thomas C.; Beier, Andreas; Ledolter, Karin; Gossenreiter, Thomas; Höfurthner, Theresa; Hartl, Markus; Baker, Terry S.; Taylor, Richard J. et al. (11 April 2023). "High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599". Proceedings of the National Academy of Sciences 120 (15). doi:10.1073/pnas.2201910120. PMID 37027427. Bibcode: 2023PNAS..12001910S.
- ↑ Price, Diana L.; Khan, Asma; Angers, Rachel; Cardenas, Alvaro; Prato, Maria Key; Bani, Massimo; Bonhaus, Douglas W.; Citron, Martin et al. (17 July 2023). "In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease" (in en). npj Parkinson's Disease 9 (1): 114. doi:10.1038/s41531-023-00552-7. ISSN 2373-8057. PMID 37460603.
- ↑ Masson, Gabrielle (16 December 2024). "UCB-Novartis Parkinson's asset fails to improve symptoms" (in en). www.fiercebiotech.com. https://www.fiercebiotech.com/biotech/ucbs-orchestra-hits-dud-note-novartis-partnered-parkinsons-asset-fails-phase-2. Retrieved 7 July 2026.
 |  |
